<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353454</url>
  </required_header>
  <id_info>
    <org_study_id>SHP625-306</org_study_id>
    <secondary_id>2017-003138-99</secondary_id>
    <nct_id>NCT03353454</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Maralixibat (SHP625) in the Treatment of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC)</brief_title>
  <official_title>Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat (SHP625) in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the investigational treatment (maralixibat) is
      safe and effective in children and adolescents with Progressive Familial Intrahepatic
      Cholestasis (PFIC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">June 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Response as measured by the Observer Itch Reported Outcome (ItchRO(Obs) ™)</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Compare the percentage of patients on active treatment vs. placebo who meet response criteria which is defined as improvement in average Observer Itch Reported Outcome (ItchRO(Obs) severity decrease from baseline on at least 2 of the last 3 study visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization or Reduction From Baseline in Serum Bile Acids (sBA)</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Compare the percentage of patients on active treatment vs. placebo with normalization or significant reduction from baseline in serum bile acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance of Pruritus as Measured by Observer Itch Reported Outcome (ItchRO(Obs)</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Compare the percentage of patients on active treatment vs. placebo of participants who experience disappearance of pruritus as measured by ItchRO(Obs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Itch Reported Outcome Instrument (ItchRO[Pt])</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Change in ItchRO(pt) ™, as completed by participants of appropriate age, will be compared between active treatment and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Height</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Proportion of participants on active treatment vs. placebo with a height z-score change from baseline &gt;0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Weight</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Proportion of participants on active treatment vs. placebo with a weight z-score change from baseline &gt;0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nutritional Status as Measured by Mid-arm Circumference</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Compare the change in nutritional status as measured by mid-arm circumference in participants on active treatment vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nutritional Status as Measured by Triceps Skin Fold</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Compare the change in nutritional status as measured by triceps skin fold in participants on active treatment vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Clinician Scratch Scale (CSS)</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Compare the change in Clinician Scratch Scale score in participants on active treatment vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life as Measured by Pediatric Quality of Life Inventory (PedsQL)</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Compare the change from baseline of PedsQL in participants on active treatment vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Sleep as Measured by Children's Sleep Habits Questionnaire (CSHQ)</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Compare the change from baseline of CSHQ in participants on active treatment vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization or meaningful reduction from baseline of Alanine aminotransferase (ALT)</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Proportion of participants whose ALT normalizes on treatment or has decreased ≥50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization or meaningful decrease from baseline of Total Bilirubin</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Proportion of participants whose total bilirubin normalizes on treatment or has decreased ≥50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Biomarkers of Bile Acid Synthesis</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Change from baseline in biomarkers of bile acid synthesis (serum 7 alpha-hydroxy-4-cholesten-3-one [C4])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety of SHP625</measure>
    <time_frame>Baseline, week 26</time_frame>
    <description>Adverse events, changes in vital signs, laboratory, and other safety parameters will be compared between participants on active treatment vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of Maralixibat Over Time</measure>
    <time_frame>Pre-dose through Week 26</time_frame>
    <description>Systemic concentrations of maralixibat in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Maralixibat (SHP625)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will recieve placebo matched to maralixibat oral solution twice daily for 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maralixibat</intervention_name>
    <description>Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.</description>
    <arm_group_label>Maralixibat (SHP625)</arm_group_label>
    <other_name>SHP625</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to maralixibat orally twice daily for 26 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Informed consent and assent (as applicable for participants less than or equal to (&lt;=)
             18 years per Institutional Review Board/Ethics Committee (IRB)/Ethics Committee (EC)
             as appropriate.

          -  Male or female participants between the ages of 12 months and 18 years inclusive
             (primary cohort) or birth to 18 years inclusive (exploratory cohort) at time of
             consent, with a body weight greater than or equal to (&gt;=) 5 kilogram (kg).

          -  Cholestasis as manifested by total sBA greater than (&gt;) 3 × upper limit of normal
             (ULN)

          -  A weekly average ItchRO(Obs) score &gt;= 1.5 during the week leading to the baseline
             visit

          -  Diagnosis of PFIC based on:

             a. Primary cohort: i. Participants with 2 documented mutant alleles in ABCB11 (PFIC2);
             participants without bile salt export pump (BSEP) function (biallelic truncating
             mutations in ABCB11) will not be enrolled into the primary cohort. b. Exploratory
             cohort: i. Participants with PFIC1/3/4 or PFIC2 with biallelic truncating
             mutationsiii.Infants from birth to &lt;12 months of age with PFIC ii. Participants with
             PFIC after internal or external (eg, PEBD) biliary diversion surgery with
             unsatisfactory pruritus control or where biliary diversion was reversed.

        Key Exclusion Criteria:

          -  Chronic diarrhea requiring intravenous fluid or nutritional intervention for the
             diarrhea and/or its sequelae.

          -  History of surgical disruption of the enterohepatic circulation (applies to primary
             cohort only).

          -  Liver transplant

          -  Decompensated cirrhosis (international normalized ratio [INR] &gt;1.5, albumin &lt;30 gram
             per liter [g/L, history or presence of clinically significant ascites, variceal
             hemorrhage, and/or encephalopathy).

          -  ALT &gt;15× ULN at screening.

          -  History or presence of other liver disease.

          -  History or presence of any other disease or condition known to interfere with the
             absorption, distribution, metabolism or excretion of drugs, including bile salt
             metabolism in the intestine (example [eg], inflammatory bowel disease), per
             investigator discretion.

          -  Liver mass on imaging

          -  Known diagnosis of human immunodeficiency virus (HIV) infection.

          -  Any prior cancer diagnosis except for in situ carcinoma or cancers treated within 5
             years of the screening visit (Visit 0) with no evidence of recurrence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholestasis</keyword>
  <keyword>Maralixibat</keyword>
  <keyword>Mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

